Strides Pharma bags USFDA approval for Ibuprofen Oral Suspension; stock marginally up

30 May 2022 , 03:09 PM

Strides Pharma Science Limited has announced that its Singapore arm, Strides Pharma Global Pte. Limited, Singapore, has secured the approval for Ibuprofen Oral Suspension USP, 100 mg/5 mL from the United States Food & Drug Administration (USFDA).

The product has the same therapeutic properties as the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil).

According to March 2022 data released by IQVIA MAT, the US market for Ibuprofen Oral Suspension USP, 100 mg/5 mL is approximately US$ 66 million.

The company will manufacture the product at its’ facility in Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

So far, the company has 274 ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA of which 250 ANDAs have been approved and 24 are pending approval.

Strides Pharma is currently trading at Rs328.45 up by Rs1.85 or 0.57% from its previous closing of Rs326.60 on the BSE. The scrip touched intraday high and low of Rs334.50 and Rs327.20 respectively.